Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

Abstract Aβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liding Zhang, Xuewei Du, Ying Su, Shiqi Niu, Yanqing Li, Xiaohan Liang, Haiming Luo
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Alzheimer’s disease Blood Aβ42 monomer Aβ42 oligomer Magnetic nanoparticles Gold nanoparticle Biotechnology TP248.13-248.65 Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/dacd0f7cb7b64f0bb340402a2b67d132
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dacd0f7cb7b64f0bb340402a2b67d132
record_format	dspace
spelling	oai:doaj.org-article:dacd0f7cb7b64f0bb340402a2b67d1322021-11-21T12:29:28ZQuantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay10.1186/s12951-021-01111-z1477-3155https://doaj.org/article/dacd0f7cb7b64f0bb340402a2b67d1322021-11-01T00:00:00Zhttps://doi.org/10.1186/s12951-021-01111-zhttps://doaj.org/toc/1477-3155Abstract Aβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ42 monomers (Aβ42Ms) and Aβ42Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ42 ELISA test kits usually mis-detected the elevated Aβ42Os, leading to incomplete analysis and underestimation of soluble Aβ42, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) using anti-Aβ42 monoclonal antibodies 1F12 and 2C6 for the rapid and point-of-care detection of Aβ42Ms and Aβ42Os in blood samples within 30 min for AD diagnosis. By naked eye observation, the visual detection limit of Aβ42Ms or/and Aβ42Os in dLFI was 154 pg/mL. The test results for dLFI were similar to those observed in the enzyme-linked immunosorbent assay (ELISA). Therefore, this paper-based dLFI provides a practical and rapid method for the on-site detection of two biomarkers in blood or CSF samples without the need for additional expertise or equipment. Graphical AbstractLiding ZhangXuewei DuYing SuShiqi NiuYanqing LiXiaohan LiangHaiming LuoBMCarticleAlzheimer’s diseaseBloodAβ42 monomerAβ42 oligomerMagnetic nanoparticlesGold nanoparticleBiotechnologyTP248.13-248.65Medical technologyR855-855.5ENJournal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-17 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Alzheimer’s disease Blood Aβ42 monomer Aβ42 oligomer Magnetic nanoparticles Gold nanoparticle Biotechnology TP248.13-248.65 Medical technology R855-855.5
spellingShingle	Alzheimer’s disease Blood Aβ42 monomer Aβ42 oligomer Magnetic nanoparticles Gold nanoparticle Biotechnology TP248.13-248.65 Medical technology R855-855.5 Liding Zhang Xuewei Du Ying Su Shiqi Niu Yanqing Li Xiaohan Liang Haiming Luo Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
description	Abstract Aβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ42 monomers (Aβ42Ms) and Aβ42Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ42 ELISA test kits usually mis-detected the elevated Aβ42Os, leading to incomplete analysis and underestimation of soluble Aβ42, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) using anti-Aβ42 monoclonal antibodies 1F12 and 2C6 for the rapid and point-of-care detection of Aβ42Ms and Aβ42Os in blood samples within 30 min for AD diagnosis. By naked eye observation, the visual detection limit of Aβ42Ms or/and Aβ42Os in dLFI was 154 pg/mL. The test results for dLFI were similar to those observed in the enzyme-linked immunosorbent assay (ELISA). Therefore, this paper-based dLFI provides a practical and rapid method for the on-site detection of two biomarkers in blood or CSF samples without the need for additional expertise or equipment. Graphical Abstract
format	article
author	Liding Zhang Xuewei Du Ying Su Shiqi Niu Yanqing Li Xiaohan Liang Haiming Luo
author_facet	Liding Zhang Xuewei Du Ying Su Shiqi Niu Yanqing Li Xiaohan Liang Haiming Luo
author_sort	Liding Zhang
title	Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
title_short	Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
title_full	Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
title_fullStr	Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
title_full_unstemmed	Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
title_sort	quantitative assessment of ad markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
publisher	BMC
publishDate	2021
url	https://doaj.org/article/dacd0f7cb7b64f0bb340402a2b67d132
work_keys_str_mv	AT lidingzhang quantitativeassessmentofadmarkersusingnakedeyespointofcaretestingwithpaperbasedlateralflowimmunoassay AT xueweidu quantitativeassessmentofadmarkersusingnakedeyespointofcaretestingwithpaperbasedlateralflowimmunoassay AT yingsu quantitativeassessmentofadmarkersusingnakedeyespointofcaretestingwithpaperbasedlateralflowimmunoassay AT shiqiniu quantitativeassessmentofadmarkersusingnakedeyespointofcaretestingwithpaperbasedlateralflowimmunoassay AT yanqingli quantitativeassessmentofadmarkersusingnakedeyespointofcaretestingwithpaperbasedlateralflowimmunoassay AT xiaohanliang quantitativeassessmentofadmarkersusingnakedeyespointofcaretestingwithpaperbasedlateralflowimmunoassay AT haimingluo quantitativeassessmentofadmarkersusingnakedeyespointofcaretestingwithpaperbasedlateralflowimmunoassay
_version_	1718418975253069824

Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

Ejemplares similares